Will any regulatory agency (FDA or EMA) approve a new CRISPR-based therapy for clinical use before 2027-06-28?

Resolves Yes if Resolves to Yes if the FDA or EMA issues marketing authorization for a therapy that uses CRISPR gene editing as its primary mechanism, for a new indication not previously approved, before the close date.

Outcome verified from fda.gov.

1. Market open

   Jun 28, 2026, 9:13 AM UTC